What were the primary drivers of the revenue increase in the third quarter?

The primary drivers of the revenue increase were pharmaceutical price appreciation, increased volume from existing customers, and contributions from acquisitions. The company also noted revenue growth from new customers, partially offset by customer losses.

Why did net earnings and operating earnings show such a significant improvement compared to the prior year's quarter?

The substantial improvement in net and operating earnings was primarily due to the absence of a $600 million reserve that was recorded in the prior year's third quarter related to shareholder litigation. Without this one-time charge, the underlying operational performance, while showing revenue growth, would not reflect such a dramatic year-over-year increase in earnings.

What is the outlook for the Healthcare Supply Chain Services – Pharmaceutical segment, and what factors are impacting its profitability?

For the Healthcare Supply Chain Services – Pharmaceutical segment, revenue grew but segment profit declined. This decline is attributed to increased customer discounts from contract repricings, the impact of generic launches in the prior year, and slower pharmaceutical market growth. The segment is also experiencing adverse effects from customer losses and expenses related to controlled substance anti-diversion efforts, which are expected to continue impacting performance.

What are the key financial activities related to capital and liquidity during the period?

Cardinal Health continued its share repurchase program, repurchasing approximately $150 million of its common shares during the quarter. Operating cash flows from continuing operations remained stable at $1.3 billion for the nine months. The company also announced a significant acquisition, Enturia Inc., for $490 million, signaling continued investment in strategic growth areas.

CAH 10-Q Quarterly Report Q3 FY2008 — Revenue, Net Income, EPS

Summary

Cardinal Health, Inc. reported solid revenue growth for the third quarter of fiscal year 2008, with revenues increasing by 5% to $22.9 billion compared to the prior year. This growth was driven by pharmaceutical price appreciation, increased volume, and contributions from acquisitions. Despite revenue growth, operating earnings saw a significant increase primarily due to the absence of a large litigation reserve recorded in the prior year's quarter. Net earnings for the quarter were $356 million, or $0.99 per diluted share, a substantial improvement from the prior year's $19 million net earnings, largely due to the aforementioned litigation expense. The company continues to manage its capital resources effectively, with operating cash flows remaining stable. Investing activities were focused on capital expenditures and acquisitions, while financing activities included significant share repurchases and debt management. The company announced a definitive agreement to acquire Enturia Inc. for $490 million, expected to close in the fourth quarter of fiscal 2008, which will be integrated into the Medical Products and Technologies segment.

Key Highlights

1Revenue increased 5% year-over-year to $22.9 billion for the third quarter of fiscal year 2008.
2Net earnings significantly improved to $356 million ($0.99 per diluted share) from $19 million ($0.05 per diluted share) in the prior year's quarter.
3The improvement in net earnings was largely due to the absence of a $600 million litigation reserve recorded in the prior year's quarter.
4Operating earnings increased to $576.5 million from a loss of $9.8 million in the prior year's quarter, driven by the absence of the litigation reserve and increased gross margin.
5The company announced an agreement to acquire Enturia Inc. for $490 million, strengthening its Medical Products and Technologies segment.
6Cash from operating activities for continuing operations remained stable at $1.3 billion for the nine months ended March 31, 2008.
7Significant share repurchases continued, with approximately $150 million repurchased in the quarter under existing authorizations.

CARDINAL HEALTH INC Quarterly Report for Q3 Ended Mar 31, 2008

Summary

Key Highlights

Frequently Asked Questions